INTC vs LRCX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Intel's deterministic health is stable with a Piotroski F-Score of 6/9, but this is overshadowed by a severe divergence between price and fundamentals. While the stock has seen a massive 1-year rally (+234.6%), the company is struggling with negative profit margins (-0.51%), declining revenue (-4.10%), and a catastrophic YoY EPS collapse of -300%. With the current price of $65.27 trading significantly above the analyst target of $55.33 and a technical trend score of 10/100, the stock appears overextended and fundamentally unsupported.
LRCX presents a dichotomy between operational excellence and valuation extremes. The Piotroski F-Score of 4/9 indicates stable financial health, but the stock is trading at a massive premium to its Graham Number ($29.53) and Intrinsic Value ($141.01). While the company boasts an exceptional ROE of 65.56% and a stellar 25-quarter earnings beat record, the technical trend (10/100) and bearish insider activity ($29.66M in sales) suggest the current price may be overextended. The company is a high-quality compounder currently priced for perfection.
Compare Another Pair
Related Comparisons
INTC vs LRCX: Head-to-Head Comparison
This page compares Intel Corporation (INTC) and Lam Research Corporation (LRCX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.